Literature DB >> 1378917

Characterization of two novel pre-B-cell lines (LK63 and LiLa-1): potential models of pre-B-cell differentiation.

E Salvaris1, J R Novotny, K Welch, L Campbell, A W Boyd.   

Abstract

In this report we describe two newly isolated pre-B acute lymphoblastic leukaemia cell lines. Both cell lines lack EBV as detected by the EBNA-1 gene probed Southern-blots. Neither cell line expressed the B-cell-specific CD20 antigen on the cell membrane. However surface expression of CD20 was induced by phorbol ester (TPA) on both LiLa-1 and LK63 cell lines. Other pre-B and B-cell lines, such as Reh, Nalm-1, and BALL-1 did not exhibit these changes in phenotype. Previous immunoprecipitation studies have noted that a broad 50-55 kD band co-precipitates with the characteristic 33-37 kD CD20 protein. We demonstrate that, while the 33-37 kD CD20 species was undetectable on resting LiLa-1 and LK63 cells, in each case a 50-55 kD protein was immunoprecipitated by the CD20 antibody. However, the failure to detect any cell surface CD20-associated antigen on the control cells by immunophenotyping indicated that the CD20 epitope of the 50-55 kD molecule was not expressed on the cell surface. Following exposure to TPA the 50-55 kD species was reduced over 48-72 h while the level of the p33-37 CD20 protein was increased. Northern-blot analysis showed that the 50-55 kD protein was not a cryptic form of CD20 as the uninduced cells contained no detectable CD20 mRNA. The decrease of the 50-55 kD protein and the acquisition of the mature CD20 molecule were paralleled by a decline in proliferative activity in both cell lines. As expression of CD20 by normal pre-B cells also coincides with the cessation of cell division and maturation towards a mature B-cell phenotype, these cell lines appear to represent models for a discrete stage of B-cell differentiation which may be valuable in defining the signals regulating pre-B-cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378917     DOI: 10.1016/0145-2126(92)90016-z

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Authors:  S Charmsaz; F Al-Ejeh; T M Yeadon; K J Miller; F M Smith; B W Stringer; A S Moore; F-T Lee; L T Cooper; C Stylianou; G T Yarranton; J Woronicz; A M Scott; M Lackmann; A W Boyd
Journal:  Leukemia       Date:  2016-12-06       Impact factor: 11.528

2.  Induction of endoplasmic reticulum calcium pump expression during early leukemic B cell differentiation.

Authors:  Lamia Aït Ghezali; Atousa Arbabian; Hervé Roudot; Jean-Philippe Brouland; Fanny Baran-Marszak; Evelyn Salvaris; Andrew Boyd; Hans G Drexler; Agnes Enyedi; Remi Letestu; Nadine Varin-Blank; Bela Papp
Journal:  J Exp Clin Cancer Res       Date:  2017-06-26

3.  mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death.

Authors:  Rana Baraz; Adam Cisterne; Philip O Saunders; John Hewson; Marilyn Thien; Jocelyn Weiss; Jordan Basnett; Kenneth F Bradstock; Linda J Bendall
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.